We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.38%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.47B
AUM Growth
+$39M
Cap. Flow
-$32.3M
Cap. Flow %
-2.19%
Top 10 Hldgs %
26.19%
Holding
101
New
9
Increased
29
Reduced
33
Closed
7

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$21.4M
2
PFE icon
Pfizer
PFE
+$19.4M
3
VEEV icon
Veeva Systems
VEEV
+$17.8M
4
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$11.9M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$11.6M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$41.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13M
3
LIVN icon
LivaNova
LIVN
+$11.9M
4
NVCR icon
NovoCure
NVCR
+$11.7M
5
CNC icon
Centene
CNC
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 94.98%
2 Industrials 1.94%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
51
DELISTED
Aerie Pharmaceuticals
AERI
$12M 0.82%
750,000
– –
XNCR icon
52
Xencor
XNCR
$1.57B
$11.7M 0.8%
340,000
+105,000
+45% +$4.16M
BDX icon
53
Becton Dickinson
BDX
$48.3B
$11.7M 0.79%
49,200
-37,925
-44% -$9.09M
EW icon
54
Edwards Lifesciences
EW
$52.8B
$11.4M 0.77%
110,000
– –
ONEM
55
DELISTED
1Life Healthcare
ONEM
$10.9M 0.74%
330,000
+130,000
+65% +$4.91M
NBIX icon
56
Neurocrine Biosciences
NBIX
$16.6B
$10.2M 0.69%
105,000
-50,000
-32% -$4.79M
FLNA
57
Filana Therapeutics
FLNA
$48.8M
$9.83M 0.67%
+115,000
New +$6.16M
SGMO
58
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9.16M 0.62%
765,000
– –
BAX icon
59
Baxter International
BAX
$14.2B
$8.86M 0.6%
110,000
-80,000
-42% -$6.71M
BMY icon
60
Bristol-Myers Squibb
BMY
$132B
$8.35M 0.57%
125,000
-200,000
-62% -$13M
IMGN
61
DELISTED
Immunogen Inc
IMGN
$8.03M 0.55%
1,218,850
+668,850
+122% +$4.67M
RVNC
62
DELISTED
Revance Therapeutics, Inc.
RVNC
$8M 0.54%
270,000
+50,000
+23% +$1.44M
RDUS
63
DELISTED
Radius Health, Inc.
RDUS
$7.84M 0.53%
430,000
– –
IOVA icon
64
Iovance Biotherapeutics
IOVA
$2.85B
$7.81M 0.53%
300,000
+5,000
+2% +$130K
ALKS icon
65
Alkermes
ALKS
$8.25B
$7.58M 0.51%
309,354
+100,000
+48% +$2.22M
EPIX
66
DELISTED
ESSA Pharma
EPIX
$7.43M 0.5%
260,000
– –
DVAX
67
DELISTED
Dynavax Technologies
DVAX
$7.39M 0.5%
750,000
-36,211
-5% -$329K
GTHX
68
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$7.13M 0.48%
325,000
– –
SILK
69
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$6.99M 0.47%
146,000
– –
MGTX icon
70
MeiraGTx Holdings
MGTX
$1.21B
$6.97M 0.47%
450,000
– –
STXS icon
71
Stereotaxis
STXS
$144M
$6.6M 0.45%
684,402
– –
RIGL icon
72
Rigel Pharmaceuticals
RIGL
$758M
$6.6M 0.45%
152,000
– –
SWAV
73
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$6.45M 0.44%
33,990
-16,010
-32% -$2.62M
PHAT icon
74
Phathom Pharmaceuticals
PHAT
$702M
$6.3M 0.43%
186,210
+11,210
+6% +$401K
ZLAB icon
75
Zai Lab
ZLAB
$2.61B
$6.2M 0.42%
35,000
-10,000
-22% -$1.61M
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Rhenman & Partners Asset Management held 101 positions worth $1.47B, up 2.7% from $1.43B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rhenman & Partners Asset Management's Q2 2021 filing shows 9 new, 29 increased, 33 reduced and 7 closed positions. Its largest new stake was Pfizer: 500,000 shares worth $19.6M. The largest sale was Johnson & Johnson, an estimated $41.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Industrials and Technology.

  • Rhenman & Partners Asset Management's largest Q2 2021 buy was Pfizer: 500,000 shares worth $19.6M.
  • Rhenman & Partners Asset Management added most to Biogen in Q2 2021, an estimated $21.4M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2021 reduction was Johnson & Johnson, cutting an estimated $41.4M.
  • Rhenman & Partners Asset Management fully exited Adverum Biotechnologies in Q2 2021, selling an estimated $6.41M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 26% of its $1.47B portfolio in Q2 2021.
  • Rhenman & Partners Asset Management opened 9 new positions and closed 7 in Q2 2021.
  • Rhenman & Partners Asset Management's portfolio value rose 2.7% quarter-over-quarter to $1.47B.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.